Cargando…

Using heparin molecules to manage COVID‐2019

The coronavirus disease 2019 (COVID‐19) pandemic is becoming one of the largest global public health crises in modern history. The race for an effective drug to prevent or treat the infection is the highest priority among health care providers, government officials, and the pharmaceutical industry....

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jian, Li, Jine, Arnold, Katelyn, Pawlinski, Rafal, Key, Nigel S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264589/ https://www.ncbi.nlm.nih.gov/pubmed/32542212 http://dx.doi.org/10.1002/rth2.12353

Ejemplares similares

Using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect against sepsis
por: Liao, Yi-En, et al.
Publicado: (2023)

Synthetic anticoagulant heparan sulfate attenuates liver ischemia reperfusion injury
por: Arnold, Katelyn, et al.
Publicado: (2020)

Protease: Serpin complexes to assess contact system and intrinsic pathway activation
por: Henderson, Michael W., et al.
Publicado: (2020)

Management of therapeutic unfractionated heparin in COVID‐19 patients: A retrospective cohort study
por: Weeks, Lachelle D., et al.
Publicado: (2021)

Argatroban in the management of heparin-induced thrombocytopenia
por: Babuin, Luciano, et al.
Publicado: (2010)

Lepirudin in the management of patients with heparin-induced thrombocytopenia
por: Petros, Sirak
Publicado: (2008)

Enzymatic Synthesis of Chondroitin Sulfate E to Attenuate Bacteria Lipopolysaccharide-Induced Organ Damage
por: Li, Jine, et al.
Publicado: (2020)

The Role of Single-Molecule Force Spectroscopy in Unraveling Typical and Autoimmune Heparin-induced Thrombocytopenia
por: Bui, Van-Chien, et al.
Publicado: (2018)

Protease Activated Receptor-2 Contributes to Heart Failure
por: Antoniak, Silvio, et al.
Publicado: (2013)

Heparin‐induced thrombocytopenia in end‐stage renal disease: Reliability of the PF4‐heparin ELISA
por: Kelly, Julie, et al.
Publicado: (2021)

Techniques for Detection of Clinical Used Heparins
por: Li, Binjie, et al.
Publicado: (2021)

Comprehensive Landscape of Heparin Therapy for COVID-19
por: Shi, Chen, et al.
Publicado: (2021)

Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing
por: Jiang, Lan, et al.
Publicado: (2022)

Low molecular weight heparin versus unfractionated heparin in the management of cerebral venous thrombosis: A systematic review and meta-analysis
por: Qureshi, Anjum, et al.
Publicado: (2017)

Heparin or nonheparin anticoagulants for VITT
por: Arnold, Donald M.
Publicado: (2022)

Development and application of global assays of hyper‐ and hypofibrinolysis
por: Ilich, Anton, et al.
Publicado: (2019)

Potential Use of Anti-Inflammatory Synthetic Heparan Sulfate to Attenuate Liver Damage
por: Arnold, Katelyn, et al.
Publicado: (2020)

Incidence of heparin-induced thrombocytopenia in patients with 2019 coronavirus disease()
por: Lozano, Roberto, et al.
Publicado: (2020)

Non-anticoagulant heparin derivatives for COVID-19 treatment
por: Cao, Min, et al.
Publicado: (2023)

General Considerations for Diversifying Heparin Drug Products by Improving the Current Heparin Manufacturing Process and Reintroducing Bovine Sourced Heparin to the US Market
por: Al-Hakim, Ali
Publicado: (2021)

Heparin – Messias or Verschlimmbesserung?
por: Swan, Dawn, et al.
Publicado: (2021)

Size of Heparin-Imprinted Nanoparticles Reflects the Matched Interactions with the Target Molecule
por: Yoshimi, Yasuo, et al.
Publicado: (2019)

Erratum: Yoshimi, Y., et al. Size of Heparin-Imprinted Nanoparticles Reflects the Matched Interactions with the Target Molecule. Sensors 2019, 19, 2415
por: Yoshimi, Yasuo, et al.
Publicado: (2019)

Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar
por: Locke, Charles FS, et al.
Publicado: (2005)

Horizons of Heparin Therapy in COVID-19 and Pandemic-Related Diseases
por: Kondashevskaya, M. V.
Publicado: (2022)

Heparin-Induced Thrombocytopenia: A Review of New Concepts in Pathogenesis, Diagnosis, and Management
por: Marchetti, Matteo, et al.
Publicado: (2021)

Introduction to the Molecules Special Edition Entitled ‘Heparan Sulfate and Heparin: Challenges and Controversies’: Some Outstanding Questions in Heparan Sulfate and Heparin Research
por: Yates, Edwin A, et al.
Publicado: (2019)

Therapeutic anticoagulation using heparin in early phase severe coronavirus disease 2019: A retrospective study
por: Takayama, Wataru, et al.
Publicado: (2022)

Heparin-induced thrombocytopenia: an update
por: Franchini, Massimo
Publicado: (2005)

Oral heparin: status review
por: Arbit, Ehud, et al.
Publicado: (2006)

Analysis and characterization of heparin impurities
por: Beni, Szabolcs, et al.
Publicado: (2010)

Heparin: Past, Present, and Future
por: Oduah, Eziafa I., et al.
Publicado: (2016)

Heparin: an intervenor in cell communication
por: Xu, Xianxiang, et al.
Publicado: (2010)

Heparin Mimetics: Their Therapeutic Potential
por: Mohamed, Shifaza, et al.
Publicado: (2017)

Autoimmune Heparin-Induced Thrombocytopenia
por: Warkentin, Theodore E.
Publicado: (2023)

A novel mouse whole blood thrombin generation assay sensitive to FXI- and FIX-mediated amplification of coagulation
por: Wan, Jun, et al.
Publicado: (2022)

Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy
por: McLaughlin, Kevin, et al.
Publicado: (2019)

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
por: Shute, Janis Kay
Publicado: (2023)

The versatile heparin in COVID‐19
por: Thachil, Jecko
Publicado: (2020)

Surviving Covid-19 with Heparin?
por: ten Cate, Hugo
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0tu55d0cupl8kl7tuc6bghj1vh